Premium
RS7435335 located in the UGT2B7 gene may be a possible genetic marker for the clinical response and prognosis of breast cancer patients receiving neoadjuvant chemotherapy
Author(s) -
Mou Peng,
Wang HuiJun,
An Liping,
Yin Qiang,
Chang Juan
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.27990
Subject(s) - medicine , oncology , breast cancer , chemotherapy , genotype , univariate analysis , predictive marker , multivariate analysis , gastroenterology , cancer , biology , gene , genetics
Objective To evaluate the predictive efficacy and prognostic value of rs7435335 located in the UGT2B7 gene as a genetic marker in breast cancer patients receiving neoadjuvant chemotherapy (NAC). Methods A total of 190 patients with breast cancer treated with NAC were enrolled to detect the rs7435335 SNP by sequenom. Miller‐Payne grades were used to evaluate the treatment efficacy. The association between rs7435335 and chemotherapy efficacy and prognosis was analyzed. Results Altogether, 42 cases (22.1%) achieved pathologic complete response (pCR). The results of the univariate analysis showed that rs7435335 had no statistically significant difference with pCR and Miller‐Payne grades ( P > 0.05). When grouping was done in accordance with the ER status, the pCR and Miller‐Payne grades significantly associated with rs7435335 ( P < 0.05) only in the ER‐negative group. Multivariate logistic regression analysis suggested that rs7435335 in the ER‐negative group was an independent predictor of pCR ( P < 0.05). Survival analysis showed that the disease‐free survival (DFS) time in patients with GA genotype was longer than that of GG genotype, and rs7435335 predicted the DFS in the ER‐negative group. Conclusion The UGT2B7 rs7435335 is associated with the NAC efficacy and prognosis. Patients with GA genotype have better efficacy and prognosis. Rs7435335 was found to be a possible gene marker for pCR and prognosis in ER‐negative patients who received NAC.